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Summary
INTRODUCTION: The prevalence of chronic kidney dis-
ease and diabetes is rising in Europe. These patients are
at high cardiovascular and renal risk and need a challeng-
ing multifactorial therapeutic approach.
METHOD: The goal of this cross-sectional study was to
examine the treatment and attainments of goals related to
cardiovascular risk factors within chronic kidney disease
stages in type 2 diabetic patients followed up by primary
care physicians in Switzerland. Each participating physi-
cian entered into a web database the anonymised data of
up to 15 consecutive diabetic patients attending her/his of-
fice between December 2013 and June 2014. Diabetes,
hypertension and lipid lowering therapies were analysed,
as well as glycated haemoglobin (HbA1c), blood pressure
and low-density lipoprotein-cholesterol (LDL-c) levels and
goal attainments by KDIGO chronic kidney disease stage
1 to 4.
RESULTS: A total of 1359 patients (mean age 66.5±12.4
years) were included by 109 primary care physicians.
Chronic kidney disease stages 0–2, 3a, 3 b and 4 were
present in 77.6%, 13.9%, 6.1%, and 2.4%, respectively.
Average HbA1c was independent of chronic kidney dis-
ease stage and close to 7%; more than half of the patients
reached the HbA1c goal. Eighty-four percent of patients
were hypertensive and only 18.2% reached the then cur-
rent Swiss or American Diabetes Association 2013 blood
pressure goals. Despite loosening of blood pressure goals
in 2015, only half of the patients reached them and most
needed multiple therapies. Increased body mass index
and advanced chronic kidney disease stage decreased
the chance of reaching blood pressure goals. Lipid low-
ering therapy was prescribed in 62.1% of cases, with av-
erage LDL-c levels similar across chronic kidney disease
stages. Only 42% of patients reached the LDL-c goal of
<2.5 mmol/l in primary prevention and 32% reached <1.8
mmol/l in secondary prevention. Younger patients were
treated significantly less aggressively than older patients
(≥68 years, median age) for HbA1c, LDL-c and diastolic
blood pressure control.
CONCLUSION: This cross-sectional study demonstrates
that blood pressure and lipid goals are less often achieved
than blood glucose control in type 2 diabetic patients fol-
lowed up by primary care physicians in Switzerland. Goal
attainments for HbA1c and LDL-c were not influenced by
chronic kidney disease stages, in contrast to blood pres-
sure. Reaching all three goals was rare (2.2%). There
is a need for improvement in blood pressure control in
advanced chronic kidney disease, whereas HbA1c goals
may be loosened in the elderly and in advanced chronic
kidney disease.
Key words: diabetes, chronic kidney disease, goal attain-
ments, HbA1c, blood pressure, LDL-cholesterol,
Introduction
Type 2 diabetes is a complex disease requiring a multifac-
torial approach. Since 1989, specific goals for blood glu-
cose, blood pressure and lipid control have been elaborated
by diabetes associations [1–3]. Recently these goals have
been adapted to diabetic patients with chronic kidney dis-
ease (CKD) in recommendations from the Kidney Disease
Outcomes Quality Initiative (KDOQI) [4], Kidney Dis-
ease: Improving Global Outcomes (KDIGO) [5], Ameri-
can Diabetes Association (ADA) and European Associa-
tion for the Study of Diabetes (EASD) [1–3]. Less strin-
gent goals for HbA1c are now recommended in CKD pa-
tients. The Steno study was the first to emphasise the
efficacy of a multifactorial approach in type 2 diabetes [6].
The group receiving intensified intervention on modifiable
risk factors for cardiovascular disease had lower cardiovas-
cular and microvascular events by around 50% compared
with those receiving usual care. In the intensive therapy
group, goals for HbA1c (goal <6.5%), systolic blood pres-
sure (goal <130 mm Hg), diastolic blood pressure (goal
<80 mm Hg) and total cholesterol (goal <175 mmol/l) were
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reached in approximately 15%, 45%, 70% and 70% of cas-
es, respectively.
Primary care physicians (PCPs) often complain about the
difficulty in reaching all goals, as time dedicated to the
care of patients in an outpatient setting is confined. Goal
attainments following recommendations have recently
been examined in the US, in Italy, in Finland and in Canada
with heterogeneous results [7–10]. For example, in a US
survey, although testing rates in family practices for
HbA1c, blood pressure and low-density lipoprotein cho-
lesterol (LDL-c) were high (99.2%, 100% and 93.9%, re-
spectively), goal attainment was not optimal. Goals were
only attained in 38.9% for HbA1c (goal <7%), in 59.5%
for blood pressure (goal <130/80 mm Hg) and in 71.8%
for LDL-c (goal <2.6 mmol/l). This was a retrospective
observational study done in a single area, showing good
adherence to ADA recommendations of practitioners in
clinics at Michigan State University. Although some coun-
tries have registries for diabetic patients, this are lacking
in Switzerland. Thus surveys with primary care physicians
are needed to examine this issue.
Objective and methods
The objective of this cross-sectional study was to examine
the treatment, the CKD stages and goal attainments of type
2 diabetic patients followed up by PCPs in Switzerland.
PCPs in German- (n = 16) and French-speaking (n = 4)
cantons were approached for this purpose.
Data were collected from December 2013 to June 2014 by
means of a cross-sectional survey of ambulatory patients
visiting their physicians. The randomisation of the par-
ticipating physicians was as follows: for the German and
French linguistic regions of Switzerland, physicians were
recruited randomly among PCPs until about 110 physi-
cians were recruited. No physician from the Italian part of
Switzerland was recruited. PCPs were asked to collect the
data from up to 15 consecutive patients with type 2 dia-
betes, without selection of enrolled patients. The data were
introduced anonymously into a web database elaborated by
PNN AG (www.pnn.ch). Informed consent was obtained
from each patient. Type 1 diabetes was an exclusion crite-
rion.
Demographic and clinical data, complications related to
diabetes, detailed antidiabetic, antihypertensive and lipid
lowering therapies, and aspirin treatment were collected
in a standardised web questionnaire. Estimated glomerular
filtration rate (eGFR) was calculated with the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI) for-
mula [5]. As data on albuminuria were available for only
a minority of patients, an eGFR ≥60 ml/min/1.73m2 was
classified as CKD stage 0–2. Detailed antidiabetic therapy
and CKD stages have been presented in a separate article
[11]. Here, we present the data for attainment of HbA1c,
blood pressure and LDL-c goals.
The study was accepted by the Ethics Committee of the
Canton of Vaud.
Data analysis for goal attainments
Blood glucose control
The most recent values for HbA1c, creatinine and antidi-
abetic therapy were introduced into the database. Mean
HbA1c values by KDIGO CKD stages [5] and age (<68 or
≥68 years) were examined. At initiation of the study, exist-
ing goals for HbA1c were individualised from <7% in pa-
tients at low risk of hypoglycaemia to <8% in patients with
a history of severe hypoglycaemia, limited life expectan-
cy, advanced microvascular complications and extensive
comorbid conditions [5, 12]. Based on these recommen-
dations, we examined HbA1c goal attainments of <7% in
CKD stage 0–2 and <8% in CKD stage 3a, 3b and 4. Fac-
tors involved in attainment of HbA1c goals were assessed.
Blood pressure control
The most recent office blood pressure reading and antihy-
pertensive therapy were entered into the database. Subjects
were stratified by KDIGO CKD stage, and the number of
antihypertensive classes analysed accordingly.
At initiation of the study, existing goals from the Swiss Hy-
pertension Society were <130/80 mm Hg in diabetes [13].
Factors involved in blood pressure goal attainment were
examined. Systolic and diastolic blood pressure levels by
KDIGO CKD stages and age (<68 or ≥68 years) were ex-
amined.
Because blood pressure goal recommendations have sub-
stantially changed during recent years [14] and differed
from Swiss recommendations at the time of the study, we
analysed the data according to a “historical” goal of <130/
80 mm Hg [13], ADA 2013 goal of <140/80 mm Hg [12],
European Society of Hypertension (ESH) 2013 goal of
<140/85 mm Hg [15] and the recent ADA 2015 goal of
<140/90 mm Hg [2].
LDL-cholesterol goals
The most recent lipid profile and lipid lowering therapy
were entered into the database. Mean LDL-c levels were
analysed by KDIGO CKD stage and median age (<68 or
≥68 years). At the initiation of the study, existing Swiss
goals for LDL-c in diabetes were <1.8 mmol/l in the case
of end-organ damage or other cardiovascular risk factors
and <2.5 mmol/l in uncomplicated type 2 diabetes [16].
We chose a goal of <1.8 mmol/l for patients with diabetes
and a positive history of coronary heart disease, atheroscle-
rosis, cerebrovascular disease and an eGFR<60ml/min. A
goal of <2.5 mmol/l was chosen for others.
Statistics
Statistical analyses were conducted using STATA® version
14 (StataCorp, College Station, TX). Continuous and cate-
gorical variables were expressed as mean ± standard devi-
ation (SD) and as number (%) of participants, respectively.
Statistical significance was a 2-sided p-value of less than
0.05. We used Pearson’s correlation to assess associations
between continuous variables. T-tests were performed to
compare continuous variables between goal attainers and
goal nonattainers. To compare the frequency of goal attain-
ers across CKD stages we used the Pearson’s chi-squared
test. We used a logistic regression to assess the associa-
tions between independent variables and goal attainment.
To compare continuous variables across CKD stages we
performed the nonparametric test for trend across ordered
groups developed by Cuzick, which is an extension of the
Wilcoxon rank-sum test [17].
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Results
A total of 109 PCPs from 20 German- or French-speaking
cantons participated in the study, with a total of 1359 pa-
tients included for analysis. Detailed geographic distribu-
tion of PCP offices has been described previously [11] (fig.
1).
Characteristics of participants according to CKD stage are
presented in table 1. There were a majority of male Cau-
casian patients. Average age was of 66.5±12.4 years (mean
± standard deviation) with most (57.5%) in the 60–80 year
group. Mean duration of diabetes was 9.3 years and mean
body mass index (BMI) 30.2 kg/m2. An eGFR ≥60 ml/
min was found in 77.6% of the patients and 13.9%, 6.1%
Figure 1: Percentage and number of type 2 diabetic patients en-
rolled by canton.ZH = Zürich; SG = St Gallen; GE = Genève; Vaud
= VD; VS = Valais; BS = Basel-Stadt; BL = Basel-Landschaft; GR
= Graubünden; LU = Luzern; TG = Thurgau; FR = Freiburg; SZ =
Schwyz; SH = Schaffhausen; AG = Aargau; OW = Obwalden; NE
= Neuchâtel; ZG = Zug; SO = Solothurn; AL = Appenzell
and 2.4%, respectively, were in CKD stage 3a, 3b and
4. Hypertension, dyslipidaemia and atherosclerosis were
the three most reported comorbidities, present in 84%,
68% and 26% of cases, respectively. Age, duration of di-
abetes, sex, smoking status, diastolic blood pressure, an-
tihypertensive therapy, lipid lowering therapy, neuropathy,
retinopathy, history of atherosclerosis, cerebrovascular dis-
ease, coronary heart disease, and heart failure differed sig-
nificantly by CKD stage.
Details of antidiabetic, antihypertensive, lipid lowering
and aspirin therapies are presented in Table 2.
Treatment and goal attainments
Glycated haemoglobin
HbA1c was available for 1357 patients. Only 6.25% of
subjects were on nonpharmacological therapy. The major-
ity of subjects were on mono- (37.7%) or dual therapy
(38.3%) with a clear preference for metformin (table 2).
Mean (± SD) HbA1c was 7.12 ± 1.22%, 7.16 ± 1.13%,
7.16 ± 1.2% and 7.18 ± 1.0%, respectively, in subjects with
stage 0–2, 3a, 3b and 4 CKD (table 1). The goal of <7%
was reached in 53% of subjects with CKD stage 0–2 (and
in 48.8% with CKD stage 3a–4); the goal of <8% was
reached in 79.1% of patients with CKD stage 3a–4. Factors
involved in HbA1c goal attainment are presented in table
3. Nonsmoking status, fewer comorbidities, increased age,
Table 1: Characteristics of participants according to stage of chronic kidney disease (n = 1359).
CKD stageVariable
0–2 3a 3b 4
Miss p-value* Total
Categorical, n (%)
Total 1057 (78.1) 183 (13.5) 84 (6.2) 30 (2.2) 5 1359
Women 430 (40.7) 81 (44.3) 45 (53.6) 19 (63.3) 2 0.01 577 (42.5)
Non-Caucasian 17 (1.6) 1 (0.5) 2 (2.4) 1 (3.3) 0 0.53 21 (1.5)
Smoking (yes) 136 (14.8) 22 (12.8) 7 (8.9) 0 (0.0) 158 0.06 165 (13.7)
Hypertension (yes) 757 (82.6) 151 (87.8) 73 (92.4) 26 (86.7) 158 0.06 1201 (84.1)
Antihypertensive TTT (yes) 782 (74.0) 165 (90.2) 77 (91.7) 29 (96.7) 0 <0.01 1056 (77.7)
Dyslipidaemia (yes) 630 (68.8) 110 (64.0) 56 (70.9) 23 (76.7) 158 0.42 822 (68.4)
Lipid lowering TTT (yes) 632 (59.8) 122 (66.7) 64 (76.2) 23 (76.7) 0 <0.01 844 (62.1)
Obesity (yes) 471 (44.6) 91 (49.7) 36 (42.9) 13 (43.3) 0 0.59 612 (45.0)
Neuropathy (yes) 111 (12.1) 34 (19.8) 21 (26.6) 12 (40.0) 158 <0.01 178 (14.8)
Retinopathy (yes) 52 (5.7) 18 (10.5) 11 (13.9) 4 (13.3) 158 <0.01 85 (7.1)
Atherosclerosis (yes) 206 (22.5) 62 (36.0) 34 (43.0) 16 (53.3) 158 <0.01 318 (26.5)
CV disease (yes) 47 (5.1) 17 (9.9) 15 (19.0) 5 (16.7) 158 <0.01 84 (7.0)
CHD (yes) 147 (16.0) 45 (26.2) 23 (29.1) 13 (43.3) 158 <0.01 228 (19.0)
Heart failure (yes) 29 (3.2) 19 (11.0) 12 (15.2) 8 (26.7) 158 <0.01 68 (5.7)
Urogenital disease (yes) 23 (2.5) 9 (5.2) 5 (6.3) 1 (3.3) 158 0.10 38 (3.2)
Continuous (mean±SD)
Age, yr 64.0±11.9 74.5±9.0 76.8±9.2 79.0±9.4 0 <0.01 66.5±12.4
Duration of DB, yr 8.9±8.7 10.9±9.7 10.4±6.3 12.5±10.8 1 <0.01 9.3±8.8
Number of DB drugs 1.72±0.88 1.60±0.83 1.73±0.94 1.43±0.90 0 0.10 1.69±0.88
Body mass index, kg/m2 30.2±5.8 30.4±5.3 30.2±5.6 30.3±5.3 1 0.55 30.2±5.7
Diastolic BP, mm Hg 80.8±9.9 78.8±11.3 77.8±12.1 73.7±9.2 0 <0.01 80.2±10.3
Systolic BP, mm Hg 136±14 137±15 138±14 138±16 0 0.11 137±14
eGFR, ml/min/1.73 m2 87.0±15.3 52.7±3.9 37.4±4.2 23.8±4.4 5 – 77.9±22.4
LDL, mmol/l 2.62±0.95 2.66±1.00 2.56±1.25 2.65±1.19 394 0.68 2.63±0.98
HDL, mmol/l 1.26±0.40 1.32±0.44 1.24±0.37 1.25±0.44 270 0.97 1.27±0.40
Triglyceride, mmol/l 1.98±1.12 1.92±1.00 2.16±1.07 1.92±0.89 275 0.61 1.97±1.09
HbA1c, % 7.12±1.22 7.16±1.13 7.16±1.20 7.18±1.00 2 0.40 7.12±1.20
BP = blood pressure; CHD = coronary heart disease; CKD = chronic kidney disease; CV = cerebrovascular disease; DB = diabetes; eGFR = estimated glomerular filtration rate;
HbA1c = glycated haemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; Miss = number of missing values; SD = standard deviation; TTT = treatment *
p-value for chi-square test of independence for categorical variables, for a trend across CKD stages for continuous variables.
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shorter duration of diabetes, lower BMI, higher HDL-c and
impaired renal function were factors associated with im-
proved HbA1c goal attainment. Mean HbA1c was 7.2% in
the group aged <68 y and 7.0% in the group aged ≥68y,
and differed significantly (p <0.01).
Blood pressure
Overall blood pressure values were available for 1359 pa-
tients. Angiotensin II receptor blockers (ARBs), diuretics
and ACE inhibitors (ACEIs) were the most prescribed an-
tihypertensive classes (46%, 45.7% and 39.7%, respective-
ly) followed by beta-blockers and calcium channel block-
ers (CCBs) (33.5% and 31.6%, respectively) (table 2).
Among the 26.2% patients on dual therapy, the preferred
option was ARB/diuretic (28.5%) followed by ACEI/di-
uretic (19.7%) and ARB/CCB (14.4%). Two patients were
on inappropriate ARB/ACEI therapy. With the progression
of CKD stages, the number of antihypertensive classes in-
creased. A total of 234/1108 (21%) of patients with blood
pressure ≥130/80 mm Hg were not on antihypertensive
therapy (fig. 2). The number of antihypertensive drugs was
the same in blood pressure goal attainers and nonattainers
(1.60 vs 1.56, p = 0.6). In blood pressure goal attainers, the
number of antihypertensive drugs increased with advanc-
ing CKD stage (p <0.001). After stratifying for two age
groups, mean systolic and diastolic blood pressure were
136.1 mm Hg and 82.6 mm Hg, respectively, in the pa-
tients aged <68 years, and 137.0 mm Hg and 77.8 mm
Hg, respectively in those aged ≥68 years (median age);
for diastolic blood pressure, the difference was significant
(p<0.01).
Estimated GFR was negatively associated with systolic
blood pressure (p <0.01) and positively associated with
diastolic blood pressure (p<0.01). Systolic blood pressure
did not differ by CKD stage; however, diastolic blood pres-
Table 2: Antidiabetic, antihypertensive, lipid lowering and aspirin therapies.
n %
Antidiabetic therapy 1359 100
Healthy way of life 1037 76.31
Pharmacological therapy 1274 93.75
Metformin 1006 74.03
DPP-4 inhibitor 465 34.22
Sulphonylurea 279 20.53
Glitazone 41 3.02
Glinide 28 2.06
Alpha glucosidase inhibitor 4 0.29
GLP-1 agonist 85 6.25
Insulin 393 28.92
Long acting insulin 273 20.09
Short and long acting insulin 182 13.39
Number of classes prescribed
0 85 6.25
1 513 37.8
2 521 38.3
3 214 15.8
4 26 1.9
Antihypertensive therapy 1056 (77.7%) answers
ACE inhibitor 420 39.7
Angiotensin receptor blocker 486 46.0
Calcium antagonist 334 31.6
Diuretic 483 45.7
Beta-blocker 354 33.5
Other 56 5.3
Number of classes prescribed
1 385 36.5
2 356 33.7
3 228 21.6
4 83 7.9
5 4 0.4
Lipid lowering therapy 844 (62.1%) answers
Statin 793 94.0
Fibrate 18 2.13
Inhibitor of cholesterol absorption 28 3.3
Other 39 4.6
Number of classes prescribed
1 810 96.0
2 34 4.0
Aspirin 1066 (78.4%) answers
575 53.9
ACE = angiotensin converting enzyme; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1
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sure was lower at advanced CKD stage (nptrend p <0.001;
table 3). The blood pressure goal of <130/80 mmg Hg was
reached in only 18.2% of patients. Of interest, a blood
pressure goal ≤130/80 mmg Hg was reached in 30% of cas-
es, illustrating a clear digit preference for numbers ending
in zero.
Factors involved in blood pressure goal attainment are pre-
sented in table 4. Presence of atherosclerosis, coronary
heart disease and congestive heart disease increased goal
attainment. Low BMI and low LDL-c levels were factors
associated with improved blood pressure goal attainment.
Figure 2: Number and % of anti-hypertensive therapy by chronic
kidney disease (CKD) stage.
Recommendations for blood pressure goals have consid-
erably changed recently and have differed between dia-
betes or hypertension associations. For better clarity, fig-
ure 3 presents different goals and goal attainments by CKD
stage. Goal attainment increased with less stringent goals
but, however, decreased with more advanced CKD. For ex-
ample, the less stringent ADA 2015 goal of a blood pres-
sure <140/90 mm Hg was reached by only 54.6%, 51.9%,
47.6%, 40%, respectively, of patients in CKD stages 0–2,
3a, 3b and 4. Goal attainment was significantly lower in
advanced CKD.
Figure 3: Mean blood pressure and number (%) of patients
achieving blood pressure goals according to guidelines.ADA =
American Diabetes Association; BP = blood pressure; ESH = Eu-
ropean Society of Hypertension
Table 3: Odd ratios for glycated haemoglobin goal attainment in univariate analysis (n = 1352).
HbA1c goal attainment
CKD stages 0–2(n = 1055) CKD stages 3a, 3b and 4(n = 297)
Independent variables Odds ratio(95% confidence inter-
val)
p-value Odds ratio(95% confidence interval) p-value
Categorical
Women 1.08 (0.84–1.38) 0.56 0.90 (0.51–1.59) 0.73
Non-Caucasian 0.48 (0.18–1.30) 0.15 0.25 (0.03–1.83) 0.17
Smoking (yes) 0.51 (0.35–0.75) <0.01 1.22 (0.44–3.35) 0.70
Hypertension (yes) 0.55 (0.39–0.78) <0.01 1.20 (0.49–2.94) 0.70
Antihypertensive TTT (yes) 0.58 (0.44–0.77) <0.01 1.48 (0.59–3.70) 0.40
Dyslipidaemia (yes) 0.79 (0.60–1.05) 0.11 0.70 (0.37–1.35) 0.29
Lipid lowering TTT (yes) 0.68 (0.53–0.88) <0.01 0.99 (0.54–1.84) 0.98
Obesity (yes) 0.67 (0.52–0.85) <0.01 0.65 (0.37–1.14) 0.13
Neuropathy (yes) 0.47 (0.31–0.71) <0.01 1.19 (0.58–2.41) 0.64
Retinopathy (yes) 0.40 (0.22–0.73) <0.01 0.44 (0.20–0.98) 0.04
Atherosclerosis (yes) 0.78 (0.57–1.06) 0.11 1.13 (0.62–2.07) 0.69
CV disease (yes) 0.82 (0.46–1.48) 0.51 0.63 (0.28–1.39) 0.25
CHD (yes) 0.83 (0.58–1.18) 0.31 0.91 (0.48–1.73) 0.78
Heart failure (yes) 1.82 (0.84–3.97) 0.13 0.96 (0.41–2.22) 0.92
Urogenital disease (yes) 0.49 (0.21–1.18) 0.11 1.00 (0.27–3.65) 0.99
Continuous
Age, 10 yr 1.18 (1.06–1.31) <0.01 1.17 (0.87–1.58) 0.30
Duration of DB, yr 0.97 (0.96–0.99) <0.01 0.97 (0.95–1.00) 0.06
Number of DB drugs 0.44 (0.37–0.51) <0.01 0.51 (0.37–0.72) <0.01
Body mass index, 5 kg/m2 0.88 (0.79–0.98) 0.02 0.82 (0.64–1.06) 0.13
Diastolic BP, 10 mmHg 0.93 (0.82–1.05) 0.24 0.76 (0.59–0.98) 0.03
Systolic BP, 10 mmHg 0.92 (0.84–1.00) 0.05 0.84 (0.69–1.02) 0.08
eGFR, 10 ml/min/1.73 m2 0.89 (0.82–0.97) <0.01 1.13 (0.87–1.46) 0.36
LDL, mmol/l 0.96 (0.83–1.12) 0.62 1.23 (0.85–1.80) 0.27
HDL, mmol/l 1.53 (1.08–2.17) 0.02 2.78 (1.09–7.14) 0.03
Triglyceride, mmol/l 0.76 (0.67–0.87) <0.01 0.58 (0.43–0.79) <0.01
HbA1c, % – – – –
BP = blood pressure; CHD = coronary heart disease; CV = cerebrovascular disease; DB = diabetes; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin;
HDL = high density lipoprotein; LDL = low density lipoprotein; TTT = treatment
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Lipids
Overall, LDL-c values were available in 965 patients.
Among the 62.1% of patients on lipid lowering therapy,
94% were taking a statin. LDL-c values were similar
across CKD stages of (mean ± SD): 2.62 ± 0.95 mmol/l,
2.66 ± 1.0 mmol/l, 2.56 ± 1.25 mmol/l and 2.65 ± 1.19
mmol/l, respectively, in subjects with CKD stages 0–2, 3a,
3b and 4 (table 1). In patients qualifying for primary pre-
vention (n = 473), an LDL-c goal of <2.5 mmol/l was
reached in 42% (n = 198) of cases. For those qualifying
for secondary prevention (n = 407), an LDL-c goal of <1.8
mmol/l was reached in 32% of cases (n = 130) (fig. 4).
LDL-c goal attainments did not change across all CKD
stages.
Figure 4: Mean low-density lipoprotein- cholesterol levels and
number (%) of patients achieving goals in primary and secondary
prevention.CKD = chronic kidney disease; LDL = low-density
lipoprotein
Factors involved in LDL-c goal attainment are presented
in table 5. Gender, smoking status and co-morbidities, age,
duration of diabetes, DBP were factors associated with im-
proved LDL goal attainment. Mean LDL-c was of 2.76
mmol/l in patients aged <68 years and 2.5 mmol/l in those
aged ≥68 years, and differed significantly between the two
age groups (p <0.01).
In this study, HbA1c, blood pressure and lipid goals were
all achieved in only 30 patients (2.2%) (fig. 5). Charac-
teristics by goal attainment are available in supplementary
table S1 (appendix).
Discussion
The European prevalence of CKD is rising in diabetic sub-
jects [18], and is the leading cause of end-stage renal dis-
Figure 5: Percentage of patients reaching glycated haemoglobin,
blood pressure and low-density lipoprotein-cholesterol goals.BP =
blood pressure; CKD = chronic kidney disease stage; HbA1c = gly-
cated haemoglobin
Table 4: Odd ratios for blood pressure goal attainment in univariate analysis (n = 1354).
Independent variables Odds ratio(95% confidence interval) p-value
Categorical
Women 1.10 (0.83–1.45) 0.52
Non-Caucasian 0.75 (0.22–2.56) 0.64
Smoking (yes) 1.12 (0.74–1.71) 0.58
Hypertension (yes) 0.48 (0.33–0.68) <0.01
Antihypertensive TTT (yes) 0.72 (0.52–0.98) 0.04
Dyslipidaemia (yes) 1.16 (0.84–1.61) 0.37
Lipid lowering TTT (yes) 1.09 (0.82–1.46) 0.54
Obesity (yes) 0.58 (0.44–0.78) <0.01
Neuropathy (yes) 1.58 (1.08–2.31) 0.02
Retinopathy (yes) 1.67 (1.01–2.79) 0.05
Atherosclerosis (yes) 1.64 (1.20–2.25) <0.01
CV disease (yes) 1.38 (0.81–2.35) 0.24
CHD (yes) 2.13 (1.52–2.99) <0.01
Heart failure (yes) 3.32 (1.99–5.53) <0.01
Urogenital disease (yes) 0.86 (0.35–2.08) 0.73
Continuous
Age, 10 yr 1.03 (0.92–1.15) 0.59
Duration of DB, yr 1.02 (1.01–1.04) <0.01
Number of DB drugs 1.07 (0.91–1.25) 0.41
Body mass index, 5 kg/m2 0.78 (0.69–0.90) <0.01
Diastolic BP, 10 mmHg – –
Systolic BP, 10 mmHg – –
eGFR, 10 ml/min/1.73 m2 0.96 (0.91–1.03) 0.25
LDL, mmol/l 0.74 (0.62–0.88) <0.01
HDL, mmol/l 0.77 (0.52–1.15) 0.21
Triglyceride, mmol/l 0.86 (0.73–1.01) 0.06
HbA1c, % 0.94 (0.83–1.06) 0.30
BP = blood pressure; CHD = coronary heart disease; CV = cerebrovascular disease; DB = diabetes; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin;
HDL = high density lipoprotein; LDL = low density lipoprotein; TTT = treatment
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ease (ESRD). The presence of nephropathy considerably
amplifies cardiovascular risk and mortality. A multifacto-
rial approach is thus necessary to decrease the renal func-
tion decline and cardiovascular risk. In accordance, guide-
lines have been released by many societies [1–4, 19] and
the goal of this study was to examine whether goal attain-
ments were reached in a primary care setting in Switzer-
land.
The average patient age, sex distribution, HbA1c, systolic
blood pressure and LDL-c level in this survey was similar
to results of other Swiss diabetic surveys [20, 21]. Our data
can therefore be considered as representative of the Swiss
diabetic population. To our knowledge, this is the first sur-
vey analysing the care of Swiss type 2 diabetic patients by
CKD stage. Overall, this study demonstrates that the ma-
jority of subjects with type 2 diabetes are men with hy-
pertension and lipid abnormalities. HbA1c goals are most
often reached, but blood pressure goals are achieved less
frequently, especially in advanced CKD stages. Among
those qualifying for secondary prevention, only a third
reached the recommended LDL-c goal.
The demographic characteristics of the population in this
survey, are similar to other studies in Europe in terms
of age group, sex and ethnicity, but differ from the US
study in which sexes were equally represented and ethnic-
ity more diverse [7–10].
HbA1c and glycaemic control
In our study, average HbA1c was independent of CKD
stage and close to 7%. This was similar to the Finnish
study, in which HbA1c ranged between 6.9 and 7.3% at
CKD stages 2–5 [9]. Thus Swiss physicians may not dif-
ferentiate their goals by CKD stage in spite of KDOQI
2012 recommendations [4]. Furthermore, older subjects
(71–90 years old) were treated significantly more aggres-
sively than younger subjects with an average HbA1c <7%.
Hence these results highlight the need to improve physi-
cian awareness of the risk of hypoglycaemia in CKD and
in the elderly [22].
Tight glycaemic control is beneficial in the primary pre-
vention of nephropathy in type 1 [23, 24] and type 2 dia-
betes [25–27], with a decrease in the incidence of microal-
buminuria and progression to macroalbuminuria, but its
effect in secondary prevention is less well established. In-
deed, the effect on renal function decline has been demon-
strated in type 1 diabetes in the 22-year Diabetes Control
and Complications Trial / Epidemiology of Diabetes In-
terventions and Complications (DCCT/EDIC) study [28],
and in subjects with type 2 diabetes after 10 years in the
UK Prospective Diabetes Study (UKPDS) study [25]. Yet
both studies involved intensive glucose control early in the
course of diabetes. The cardiovascular and renal efficacy
and safety of tight glycaemic control in type 2 diabetes
patients at high cardiovascular risk needs to be careful-
Table 5: Odd ratios for low-density lipoprotein goal attainment in univariate analysis (n = 937).
LDL goal attainment
CKD stages 0–2 n = 748) CKD stages 3a, 3b and 4(n = 189)
Independent variables Odds ratio(95% confidence inter-
val)
p-value Odds ratio(95% confidence
interval)
p-value
Categorical
Women 0.67 (0.49–0.91) 0.01 0.55 (0.28–1.07) 0.08
Non-Caucasian 0.68 (0.24–1.95) 0.47 * *
Smoking (yes) 0.56 (0.35–0.88) 0.01 0.99 (0.30–3.25) 0.98
Atherosclerosis (yes) – – – –
Hypertension (yes) 1.15 (0.77–1.72) 0.48 1.12 (0.38–3.26) 0.84
Antihypertensive TTT (yes) 2.04 (1.39–2.99) <0.01 4.50 (0.57–35.55) 0.15
Dyslipidaemia (yes) 1.31 (0.94–1.83) 0.11 0.62 (0.31–1.24) 0.17
Lipid lowering TTT (yes) 2.85 (2.03–4.01) <0.01 1.78 (0.79–4.00) 0.16
Obesity (yes) 1.29 (0.96–1.73) 0.10 1.17 (0.61–2.25) 0.63
Neuropathy (yes) 1.99 (1.26–3.15) <0.01 1.47 (0.67–3.24) 0.33
Retinopathy (yes) 2.55 (1.29–5.06) 0.01 2.40 (0.89–6.49) 0.08
CV disease (yes) – – – –
CHD (yes) – – – –
Heart failure (yes) 2.19 (0.92–5.19) 0.08 1.80 (0.70–4.65) 0.22
Urogenital disease (yes) 1.15 (0.42–3.13) 0.78 1.88 (0.51–6.97) 0.34
Continuous
Age, 10 yr 1.20 (1.05–1.38) 0.01 1.19 (0.80–1.77) 0.40
Duration of DB, yr 1.02 (1.01–1.04) 0.01 1.01 (0.98–1.04) 0.54
Number of DB drugs 1.18 (1.00–1.40) 0.06 0.86 (0.59–1.25) 0.42
Body mass index, 5 kg/m2 1.12 (0.99–1.27) 0.08 1.15 (0.86–1.53) 0.34
Diastolic BP, 10 mm Hg 0.77 (0.66–0.91) <0.01 0.82 (0.60–1.10) 0.19
Systolic BP, 10 mm Hg 0.99 (0.89–1.11) 0.89 0.79 (0.63–1.01) 0.06
eGFR, 10 ml/min/1.73 m2 0.92 (0.84–1.02) 0.10 0.78 (0.59–1.04) 0.09
LDL, mmol/l – – – –
HDL, mmol/l 1.04 (0.72–1.51) 0.84 0.63 (0.27–1.48) 0.29
Triglyceride, mmol/l 0.99 (0.82–1.20) 0.91 0.97 (0.64–1.46) 0.87
HbA1c, % 0.96 (0.85–1.09) 0.51 1.20 (0.91–1.59) 0.19
BP = blood pressure; CHD = coronary heart disease; CV = cerebrovascular disease; DB = diabetes; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin;
HDL = high density lipoprotein; LDL = low density lipoprotein; TTT = treatment * Too few (4) non-Caucasian participants with CKD stages 3a, 3b and 4 to perform a univariate
analysis
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ly investigated [26, 27]. The ACCORD (Action to Con-
trol Cardiovascular Risk in Diabetes), ADVANCE (Action
in Diabetes and Vascular Disease: Preterax and Diamicron
MR Controlled Evaluation) and VADT (Veteran's Affairs
Diabetes Trial) trials showed an improvement in the pre-
vention and progression of albuminuria with tight gly-
caemic control, but no benefits on renal function decline
in high risk subjects with type 2 diabetes and cardiovas-
cular disease. These studies, however, excluded subjects
with creatinine levels over 130 to 140 µmol/l. Eventually,
a post hoc analysis of the ADVANCE trial did show a sig-
nificant reduction in the risk of ESRD, although numbers
were low and the number needed to treat (NNT) was 445
to prevent one case of ESRD in 5 years [29]. This was
recently confirmed in the ADVANCE-ON follow-up trial,
which found an NNT of 109 for CKD stages 1–2 and 393
for CKD stages 3 or greater to prevent one case of ESRD
over 9.9 years of follow-up [30]. A recent and important
study demonstrated a decrease in new onset or worsening
of nephropathy in patients with diabetes and established
cardiovascular disease treated with empagliflozin, a sodi-
um-glucose cotransporter 2 (SGLT-2) inhibitor [31]. Most
experts agree that the nephroprotection provided by em-
pagliflozin is not due to the mild improvement in blood
glucose but to many other hemodynamic and metabolic
effects currently under investigation [32]. As SGLT-2 in-
hibitors reached the market in mid-2014, no patients in this
study were on this treatment.
CKD is associated with an increased risk of hypogly-
caemia [33], which could increase mortality [34, 35]. The
ACCORD study was prematurely stopped because of in-
creased all-cause mortality rate in the intensive interven-
tion arm (HbA1c goal <6%) [33]. Consequently, the KDO-
QI clinical practice guidelines published in 2012 recom-
mend not targeting an HbA1c of <7% in CKD patients
at risk of hypoglycaemia [4]. Likewise, the ADA recom-
mends a personalised target based on age, comorbidities,
disease duration, life expectancy, risk of hypoglycaemia,
patient attitude and patient resource [1]. In our study, goal
attainment was obviously easier to reach in CKD stages 3
to 4 because it was loosened to <8%.
Blood pressure
Similar to the Finnish and Canadian surveys, in this survey
the large majority of subjects were hypertensive [9, 10] and
only half reached the ADA 2015 goals for blood pressure
and even fewer the more stringent ADA 2013 goals pre-
vailing during the study [2]. Advanced CKD stage was as-
sociated with multiple antihypertensive drugs and reduced
ADA 2015 goal attainment, as found in the Finnish popu-
lation [9]. Last digit preference suggests that PCPs round
measured values, which can significantly bias the analysis
for goal attainment if < or ≤ are chosen for blood pressure
target values. This phenomenon has been described when
physicians use manual as well as automatic blood pressure
measuring devices [36].
Targeting blood pressure levels is a priority in the care of
patients with type 2 diabetes. Reduction in cardiovascular
events with lower blood pressure has been demonstrated
in a large number of randomised control trials including
diabetic patients [37]. Tight systolic blood pressure con-
trol (≤130 mm Hg) decreased stroke and overt nephropa-
thy, but not all-cause mortality, whereas less tight control
(≤135 mm Hg) decreased all-cause mortality [38]. Other
studies showed a decrease in the incidence and progression
of nephropathy with systolic blood pressure <140 mm Hg
[39–41]. Therefore, blood pressure goals have been loos-
ened from <130/80 mm Hg before 2013 to <140/90 mm
Hg (or <130/80 mm Hg in case of stage A2–A3 albu-
minuria) in 2015 [2]. Our study demonstrates that, despite
loosening of goals, only half of patients reach them and
most needed multiple therapies. The fact that a fifth of pa-
tients not at goal were not on antihypertensive drug thera-
py emphasises the problem of medical inertia and the need
of continual PCP education.
In our study, blockade of the renin angiotensin system with
ARBs or ACE inhibition and diuretics were clearly the pre-
ferred options for antihypertensive therapy. The KDIGO
2012 and KDOQI recommendations propose an ARB or
ACEI as first line therapy in diabetic hypertensive subjects
with albuminuria (stage A2 or more) [4, 42]. Nephropro-
tection with irbesartan and losartan has been demonstrated
in CKD type 2 diabetic patients independent of blood pres-
sure reduction [41, 43]. Although the KDIGO guidelines
do not recommend specific second-line therapy, amlodip-
ine could be preferred to hydrochlorothiazide because of
superior efficacy in the reduction of cardiovascular events
and the progression of CKD in hypertensive subjects at
high cardiovascular risk on ACE inhibition [44]. In our
study, we showed that multiple drug regimens were needed
more with advanced CKD stages, as already demonstrat-
ed in a cross-sectional observational Swiss survey includ-
ing diabetic and CKD patients visiting PCPs [45]. Multi-
medication and comorbidities are a cause of nonadherence
to treatment [46], which could be improved by single pill
combination therapy and clinical pharmacist evaluation of
adverse effects and drug interactions [45].
Lipids
Lipid lowering therapy was prescribed in 62.1% of our pa-
tients, similarly to the Finnish study [9] and fewer than half
of the patients reached the goal of <2.5 mmol/l for primary
prevention. This rate fell to a third for those qualifying for
secondary prevention. Interestingly, CKD was not a limit-
ing factor for lipid goal attainment. Better results were re-
ported in the Canadian survey, with 82% of type 2 diabet-
ic patients taking lipid-lowering therapy and 57% attaining
the defined LDL-c goal of ≤2.0 mmol/l [10]. To explain
these low rates of success, low adherence to treatment, pa-
tient education and/or limited access to medical care were
highlighted. Likewise, in a Swiss survey including 19.7%
of diabetics, diabetes was a predictor for treatment non-
adherence. Also, although diabetes was as a positive pre-
dictor for diagnostic adherence, it was not a predictor for
overall guideline adherence, highlighting the difficulty in
reaching lipid treatment goals in diabetes [47].
Patients with diabetes and CKD represent a very high car-
diovascular risk group [48, 49]. The Study of Heart and
Renal Protection (SHARP) demonstrated a decrease in car-
diovascular events for stage 3a–5 CKD patients who were
on statin/ezetimibe combination therapy. However, no sig-
nificant effect was observed for mortality or the progres-
sion of renal disease [50]. Statin or statin/ezetimibe com-
bination is recommended as the first line LDL-c therapy,
regardless of the baseline values, in nondialysis diabetic
CKD patients [2, 51]. Current recommendations for pa-
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tients with diabetes and CKD do not specify any LDL-c
goal [2, 51]. However, after initiating lipid lowering thera-
py, measuring LDL-c is optional to assess patient drug ad-
herence. Doses of lipid lowering agents should be adapted
to renal function as side effects are more prevalent and se-
rious in this population [52].
Interestingly, this study showed that patients aged >68
years have significantly lower levels of LDL-c compared
with younger patients. An Italian survey among diabetic
CKD patients also showed that LDL-c goal was attained
less often by younger adults than older adults [8]. Drug ad-
herence is known to be lowest in younger adults, specif-
ically in younger men. Recently, another Italian survey
demonstrated a higher all-cause mortality and cardiovascu-
lar mortality in younger (<75 years) CKD diabetic patients
[53], which may be due to a difficulty in reaching goals for
cardiovascular risk factors in this younger population. This
will need further investigation.
Limitations of the study
As our sampling method was not truly random (i.e., ran-
domly choosing participating physicians) but based on the
willingness of physicians to participate to the study, the
sample studied may not be representative of the population
as found in a population-based cohort study. We cannot ex-
clude the possibility that physicians agreeing to participate
in the study were more compliant with current recommen-
dations than those who refused. Furthermore, patients se-
lected for the data collection obviously represent a group
more adherent to visits to physician offices, and men in this
case may be underrepresented. This may have created a
considerable bias in selection. The observational design of
this study does not allow the reasons why targets were not
achieved to be identified. Finally, in this study it was not
possible to differentiate between non-CKD patients and
patients with CKD stage 1 to 2 because of insufficient re-
porting of albuminuria. Devices for blood pressure mea-
surements and the number of blood pressure measurements
were not standardised. Because of the known white coat
effect, the percentage of patients attaining blood pressure
goals might have been underestimated. Laboratory mea-
surements were not standardised and based on single val-
ues.
Ideally, the results of this study should be compared with
those found in a population-based cohort study. Further-
more, barriers to patient and physician compliance should
be assessed in order to implement strategies to improve
goal attainments.
Conclusion
This cross-sectional study demonstrates that blood pres-
sure and lipid goal attainments are less often achieved than
blood glucose control in type 2 diabetic patients followed
up by PCPs in Switzerland. Reaching all goals current in
2013 was close to impossible. Goal attainments for HbA1c
and LDL-c were not influenced by CKD stage. HbA1c
and LDL-c were less well controlled in younger individu-
als. There is a need for improvement in cardiovascular risk
control in the younger population, blood pressure control
in advanced CKD, whereas HbA1c goals may be loosened
in the elderly and in advanced CKD.
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Appendix Supplementary table
Table S1: Patient characteristics by goal attainment.
Hba1c goal attained BP goal attained LDL goal attained
Independent variables No Yes No Yes No Yes
Categorical
Total 557 795 1110 249 607 332
Women 228 346 467 110 280 116
Men 329 449 643 139 327 216
Continuous
Age, yr 64.1±12.0 68.3±12.3 66.4±12.0 66.7±13.7 67.0±12.6 68.2±10.4
Body mass index, kg/m2 30.7± 5.3 29.9± 5.9 30.5± 5.7 29.0± 5.5 29.9± 5.8 30.7± 5.7
Diastolic BP, mm Hg 81±10 79± 10 82± 10 70± 6 80± 10 78±10
Systolic BP, mm Hg 138±15 136±14 140±12 119±7 136±14 136±14
eGFR, ml/min/1.73 m2 83.5±20.5 73.8±22.8 78.2±22.2 76.4±23.1 77.7±22.5 79.0±20.7
LDL, mmol/l 2.63±1.02 2.63±0.95 2.68±1.00 2.41±0.86 3.14±0.82 1.71±0.45
HDL, mmol/l 1.22±0.40 1.30±0.41 1.27±0.41 1.24±0.37 1.28±0.37 1.26±0.46
Triglyceride, mmol/l 2.18±1.17 1.84±1.02 2.00±1.10 1.84±1.06 1.83±0.74 1.82±0.83
HbA1c, % 8.18±1.10 6.39±0.55 7.14±1.23 7.04±1.10 7.04±1.21 7.04±1.10
BP = blood pressure; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein
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